tafenoquine has been researched along with Infections, Plasmodium in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.00) | 18.7374 |
| 1990's | 6 (12.00) | 18.2507 |
| 2000's | 10 (20.00) | 29.6817 |
| 2010's | 25 (50.00) | 24.3611 |
| 2020's | 7 (14.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blumbergs, P; LaMontagne, MP; Smith, DC | 1 |
| Ager, A; Ellis, W; Guan, J; Kyle, D; Lin, AJ; Milhous, W; Sacci, J; Zhang, Q | 1 |
| Charles, BG; Edstein, MD; Harris, IE; Miller, AK; Nasveld, PE; Reid, MG | 1 |
| Ager, AL; Bartlett, MS; Croft, SL; Khan, IA; McChesney, JD; Nanayakkara, NP; Walker, LA; Yardley, V | 1 |
| Brennan, L; Edstein, MD; Harris, IE; Kerr, C; Kitchener, SJ; Leggat, PA; Nasveld, PE; Ohrt, C; Pickford, P; Prescott, W; Reid, M | 1 |
| Hudson, TH; Kozar, MP; Lin, AJ; Magill, AJ; Melendez, V; Ohrt, C; Shiraki, H | 1 |
| Kozar, MP; Li, Q; Lin, AJ; Liu, X; Melendez, V; O'Neil, MT; Wang, X | 1 |
| Caridha, D; Kozar, MP; Lin, AJ; O'Neil, MT; Pybus, B; Sathunuru, R; Zhang, L | 1 |
| Avery, VM; Baragaña, B; Campbell, SF; Delves, MJ; Duffy, S; Fairlamb, AH; Frearson, JA; Gilbert, IH; Gray, DW; Grimaldi, R; Hallyburton, I; Meister, S; Norcross, NR; Norval, S; Osuna-Cabello, M; Porzelle, A; Read, KD; Riley, J; Simeons, FR; Sinden, RE; Stojanovski, L; Waterson, D; Willis, P; Wilson, C; Winzeler, EA; Wittlin, S; Wyatt, PG | 1 |
| Attaher, O; Bousema, T; Bradley, J; Diallo, M; Dicko, A; Dicko, OM; Drakeley, C; Issiaka, D; Keita, S; Lanke, K; Maguiraga, SO; Mahamar, A; McCall, MBB; Niambele, SM; Sacko, A; Samake, S; Sanogo, K; Sinaba, Y; Smit, MJ; Stone, W; Ter Heine, R; Traore, SF | 1 |
| Baird, JK; Berni, A; Budiman, W; Cedar, E; Chand, K; Crenna-Darusallam, C; Duparc, S; Ekawati, LL; Elyazar, I; Fernando, D; Fletcher, K; Goyal, N; Green, JA; Instiaty, I; Jones, S; Kleim, JP; Lardo, S; Martin, A; Noviyanti, R; Prasetya, CB; Rolfe, K; Santy, YW; Satyagraha, AW; Sharma, H; Soebandrio, A; Subekti, D; Sutanto, I; Tan, LK; Taylor, M | 1 |
| Bassat, Q; Brito-Sousa, JD; Costa, FT; King, L; Lacerda, MV; Luzzatto, L; Monteiro, WM; Siqueira, AM; Val, F | 1 |
| Haston, JC; Hwang, J; Tan, KR | 1 |
| Commons, RJ; McCarthy, JS; Price, RN | 1 |
| Carr, KA; Clarke, JG; Kreishman-Deitrick, M; Shmuklarsky, MJ; Zottig, VE | 1 |
| Calvaresi, EC; Genzen, JR | 1 |
| Clark, J; Clements, ACA; Doi, SAR; Furuya-Kanamori, L; Islam, N; Lau, CL; Mills, DJ; Wright, S | 1 |
| Baird, JK | 2 |
| Ashley, EA; Phyo, AP | 1 |
| Frampton, JE | 1 |
| Fukuda, MM; Martin, N; Waters, NC; Wojnarski, M; Zottig, V | 1 |
| Freedman, DO | 1 |
| Meltzer, E; Schwartz, E | 1 |
| Kain, KC | 1 |
| Chu, CS; Freedman, DO | 1 |
| Mordue, DG; Wormser, GP | 1 |
| Fernando, SD; Rajapakse, S; Rodrigo, C | 1 |
| Shanks, GD | 1 |
| Bennett, JW; Careagabarja, J; Caridha, D; Deye, G; Dhammika Nanayakkara, NP; Hickman, M; Li, Q; Marcsisin, SR; McNulty, R; Melendez, V; Pybus, BS; Read, L; Reichard, GA; Roncal, N; Sciotti, RJ; Smith, B; Sousa, JC; Walker, LA; Zeng, Q; Zottig, VE | 1 |
| Caridha, D; Hickman, M; Li, Q; Melendez, V; O'Neil, M; Pybus, B; Xie, L; Zeng, Q; Zhang, J | 1 |
| Berman, J; DiTusa, C; Gettayacamin, M; Im-erbsin, R; Kozar, MP; Ohrt, C; Pybus, B; Sousa, J; Tungtaeng, A | 1 |
| deKock, C; Dube, A; Gibhard, L; Hayeshi, R; Kalombo, L; Melariri, P; Nkuna, P; Ogutu, B; Smith, P; Swai, H; Wiesner, L | 1 |
| Berman, J; Caridha, D; Dickson, SP; Hickman, M; Lee, PJ; Li, Q; Marcsisin, SR; Milner, EE; Read, LT; Roncal, N; Vesely, BA; Xie, LH; Zhang, J; Zhang, P | 1 |
| Cozens, S; Dow, GS; Gettayacamin, M; Hansukjariya, P; Imerbsin, R; Kenworthy, D; Komcharoen, S; Kyle, D; Milhous, W; Miller, A; Ohrt, C; Sattabongkot, J; Veazey, J | 1 |
| Dutta, GP; Puri, SK | 1 |
| Peters, W; Robinson, BL; Stewart, LB | 1 |
| Jomaa, H; Ortmann, R; Schlitzer, M; Wiesner, J | 1 |
| Chambers, JA | 1 |
| Milhous, WK; Peters, W; Robinson, BL | 1 |
| Fleck, SL; Peters, W; Robinson, BL | 1 |
| Peters, W | 1 |
| Kremsner, P | 1 |
| Kain, KC; Keystone, JS; Shanks, GD | 1 |
| Eamsila, C; Edstein, MD; Kitchener, S; Nasveld, PE; Rieckmann, KH; Sasiprapha, T; Walsh, DS | 1 |
| Trigg, PI | 1 |
| Coleman, RE | 1 |
| Gutteridge, WE | 1 |
13 review(s) available for tafenoquine and Infections, Plasmodium
| Article | Year |
|---|---|
Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019.
Topics: Aminoquinolines; Antimalarials; Centers for Disease Control and Prevention, U.S.; Humans; Malaria; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Secondary Prevention; Travel Medicine; United States | 2019 |
Efficacy of a 3-day pretravel schedule of tafenoquine for malaria chemoprophylaxis: a network meta-analysis.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria; Mefloquine; Network Meta-Analysis; Travel | 2021 |
Drugs in Development for Malaria.
Topics: Aminoquinolines; Antimalarials; Artemisinins; Drug Discovery; Drug Resistance, Multiple; Ferrous Compounds; Humans; Imidazoles; Lumefantrine; Malaria; Metallocenes; Piperazines; Signal Transduction; Treatment Outcome | 2018 |
Tafenoquine: First Global Approval.
Topics: Aminoquinolines; Antimalarials; Drug Approval; Humans; Malaria; Treatment Outcome; United States; United States Food and Drug Administration | 2018 |
Tafenoquine and G6PD: a primer for clinicians.
Topics: Aminoquinolines; Antimalarials; Contraindications, Drug; Dose-Response Relationship, Drug; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria; Randomized Controlled Trials as Topic; Recurrence | 2019 |
Tafenoquine for primary and terminal prophylaxis of malaria in apparently healthy people: a systematic review.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria; Treatment Outcome | 2019 |
Expanded table: drugs for prophylaxis of malaria.
Topics: Aminoquinolines; Antimalarials; Atovaquone; Drug Combinations; Humans; Malaria; Pre-Exposure Prophylaxis; Statistics as Topic; Travel | 2019 |
New antimalarial drugs.
Topics: Aminoquinolines; Animals; Antimalarials; Artemisinins; Artesunate; Atovaquone; Clinical Trials as Topic; Dapsone; Drug Combinations; Drug Design; Drug Resistance; Ethanolamines; Flavonoids; Fluorenes; Fosfomycin; Global Health; Humans; Lumefantrine; Malaria; Naphthoquinones; Naphthyridines; Plasmodium falciparum; Proguanil; Sesquiterpenes | 2003 |
Military aviators, special operations forces, and causal malaria prophylaxis.
Topics: Aminoquinolines; Antimalarials; Atovaquone; Aviation; Chloroquine; Doxycycline; Drug Combinations; Humans; Malaria; Mefloquine; Military Personnel; Naphthoquinones; Primaquine; Proguanil; United States | 2003 |
The evolution of tafenoquine--antimalarial for a new millennium?
Topics: Aminoquinolines; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Primaquine | 1999 |
Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future.
Topics: Aminoquinolines; Animals; Antimalarials; Drug Resistance; Humans; Malaria; Plasmodium; Primaquine; Travel | 2001 |
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Military Personnel; Primaquine | 2001 |
Antimalarial drugs currently in development.
Topics: Aminoquinolines; Antimalarials; Artemisinins; Atovaquone; Chemical Phenomena; Chemistry; Drug Design; Drug Evaluation, Preclinical; Drug Resistance; Humans; Malaria; Naphthoquinones; Research; Sesquiterpenes | 1989 |
5 trial(s) available for tafenoquine and Infections, Plasmodium
| Article | Year |
|---|---|
Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Double-Blind Method; Female; Humans; Malaria; Male; Middle Aged; Military Personnel; Models, Biological | 2007 |
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Topics: Adult; Aminoquinolines; Antimalarials; Australia; Double-Blind Method; Female; Humans; Malaria; Male; Mefloquine; Middle Aged; Military Personnel; Treatment Outcome; Young Adult | 2010 |
Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.
Topics: Aminoquinolines; Animals; Artemisinins; Humans; Malaria; Malaria, Falciparum; Mali; Piperazines; Plasmodium falciparum; Quinolines; Single-Blind Method | 2022 |
Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Therapy, Combination; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine; Quinolines | 2023 |
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Military Personnel; Primaquine | 2001 |
33 other study(ies) available for tafenoquine and Infections, Plasmodium
| Article | Year |
|---|---|
Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.
Topics: Aminoquinolines; Animals; Antimalarials; Chemical Phenomena; Chemistry; Malaria; Mice; Plasmodium berghei; Structure-Activity Relationship | 1989 |
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
Topics: Administration, Oral; Animals; Antimalarials; Carbamates; Guanidines; Imidazoles; Imidazolidines; Malaria; Male; Mice; Plasmodium falciparum; Plasmodium yoelii; Structure-Activity Relationship | 2005 |
Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.
Topics: Aminoquinolines; Animals; Antifungal Agents; Antiprotozoal Agents; Dogs; Female; Hemolysis; Humans; Leishmania donovani; Leishmaniasis, Visceral; Malaria; Male; Methemoglobinemia; Mice; Mice, Inbred BALB C; Plasmodium berghei; Pneumocystis carinii; Pneumonia, Pneumocystis; Stereoisomerism; Structure-Activity Relationship | 2008 |
Antimalarial activity of novel 5-aryl-8-aminoquinoline derivatives.
Topics: Aminoquinolines; Animals; Antimalarials; Cell Line; Chloroquine; Drug Resistance; Humans; In Vitro Techniques; Malaria; Mice; Microsomes, Liver; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship | 2011 |
Synthesis and antimalarial activity of 2-guanidino-4-oxoimidazoline derivatives.
Topics: Administration, Oral; Animals; Antimalarials; Guanidines; Imidazolidines; Imidazolines; Macaca mulatta; Malaria; Mice; Plasmodium berghei; Plasmodium cynomolgi; Plasmodium falciparum; Prodrugs; Structure-Activity Relationship | 2011 |
Antimalarial activities of new guanidylimidazole and guanidylimidazoline derivatives.
Topics: Animals; Antimalarials; Crystallography, X-Ray; Guanidines; Humans; Imidazoles; Imidazolines; In Vitro Techniques; Macaca mulatta; Malaria; Mice; Microsomes, Liver; Plasmodium berghei; Plasmodium falciparum; Recurrence; Structure-Activity Relationship | 2011 |
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
Topics: Animals; Antimalarials; Disease Models, Animal; Drug Discovery; Malaria; Mice; Molecular Structure; Plasmodium falciparum; Quinolines; Structure-Activity Relationship | 2016 |
Tafenoquine for the prophylaxis, treatment and elimination of malaria: eagerness must meet prudence.
Topics: Aminoquinolines; Animals; Antimalarials; Drug Evaluation; Humans; Malaria; Plasmodium vivax; Randomized Controlled Trials as Topic | 2019 |
Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency.
Topics: Aminoquinolines; Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; Male; Practice Guidelines as Topic; Primaquine | 2020 |
Army Antimalarial Drug Development: An Advanced Development Case Study for Tafenoquine.
Topics: Aminoquinolines; Antimalarials; Drug Development; Humans; Malaria; Military Personnel | 2020 |
Evaluating Percentage-Based Reporting of Glucose-6-Phosphate Dehydrogenase (G6PD) Enzymatic Activity.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Child; Child, Preschool; Female; Glucosephosphate Dehydrogenase; Hematologic Tests; Humans; Infant; Malaria; Male; Middle Aged; Reference Values; Retrospective Studies; Young Adult | 2020 |
Single loading-dose tafenoquine for malaria chemoprophylaxis during brief travel?
Topics: Aminoquinolines; Chemoprevention; Humans; Malaria | 2021 |
Tafenoquine for travelers' malaria: evidence, rationale and recommendations.
Topics: Adult; Aminoquinolines; Antimalarials; Dose-Response Relationship, Drug; Female; Humans; Infection Control; Malaria; Malaria, Vivax; Male; Travel; United States; United States Food and Drug Administration | 2018 |
Editorial: Malaria in the Korean peninsula: Risk factors, latent infections, and the possible role of tafenoquine, a new antimalarial weapon.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria; Military Personnel | 2018 |
Tafenoquine: integrating a new drug for malaria prophylaxis into travel medicine practice.
Topics: Aminoquinolines; Humans; Malaria; Travel; Travel Medicine | 2019 |
Atovaquone-proguanil chemoprophylaxis in the era of Tafenoquine.
Topics: Aminoquinolines; Antimalarials; Atovaquone; Chemoprevention; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Proguanil; Travel | 2019 |
Single-dose radical cure for Plasmodium vivax.
Topics: Aminoquinolines; Humans; Malaria; Plasmodium vivax; Primaquine; Travel | 2019 |
Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?
Topics: Aminoquinolines; Animals; Babesia microti; Babesiosis; Female; Malaria; Mice; Mice, SCID; Parasitemia; Plasmodium | 2019 |
Tafenoquine (Arakoda; Krintafel) for malaria.
Topics: Aminoquinolines; Antimalarials; Delayed-Action Preparations; Humans; Malaria; Randomized Controlled Trials as Topic; Travel | 2019 |
Possible options for malaria chemoprophylaxis on the horizon.
Topics: Aminoquinolines; Antimalarials; Azithromycin; Chemoprevention; Doxycycline; Drug Therapy, Combination; Humans; Malaria; Medication Adherence; Primaquine | 1999 |
Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.
Topics: Aminoquinolines; Animals; Antimalarials; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Malaria; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plasmodium berghei; Succinates | 2014 |
Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.
Topics: Aminoquinolines; Animals; Antimalarials; Area Under Curve; Flow Cytometry; Half-Life; Liver; Malaria; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Plasmodium berghei; Primaquine; Sporozoites | 2014 |
Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model.
Topics: Aminoquinolines; Animals; Antimalarials; Atovaquone; Disease Models, Animal; Drug Combinations; Macaca mulatta; Malaria; Parasitemia; Plasmodium cynomolgi; Primaquine; Proguanil | 2014 |
Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice.
Topics: Administration, Oral; Aminoquinolines; Animals; Antimalarials; Biological Availability; Erythrocytes; Humans; Malaria; Mice; Nanostructures; Plasmodium berghei; Plasmodium falciparum | 2015 |
Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.
Topics: Aminoquinolines; Animals; Antimalarials; Chemoprevention; Cytochrome P-450 CYP2D6; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy; Female; Malaria; Male; Mice, Inbred C57BL; Mice, Knockout; Plasmodium berghei; Primaquine; Treatment Outcome | 2016 |
Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta).
Topics: Aminoquinolines; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chloroquine; Chromatography, Liquid; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Macaca mulatta; Malaria; Male; Mass Spectrometry; Mefloquine; Plasma; Plasmodium cynomolgi; Primate Diseases; Quinine; Treatment Outcome | 2011 |
Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys.
Topics: Aminoquinolines; Animals; Antimalarials; Female; Macaca mulatta; Malaria; Male; Monkey Diseases; Parasitemia; Plasmodium cynomolgi; Primaquine | 2003 |
The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Drug Therapy, Combination; Malaria; Malaria, Falciparum; Malaria, Vivax; Mefloquine; Mice; Plasmodium berghei; Plasmodium chabaudi; Plasmodium yoelii; Primaquine; Time Factors | 2003 |
The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Malaria; Mice; Plasmodium berghei; Plasmodium yoelii | 1993 |
The chemotherapy of rodent malaria. LIV. Combinations of 'Fenozan B07' (Fenozan-50F), a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane, with other drugs against drug-sensitive and drug-resistant parasites.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Drug Antagonism; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Malaria; Mefloquine; Mice; Naphthyridines; Parasitemia; Phenanthrenes; Phenylpropionates; Plasmodium berghei; Plasmodium yoelii | 1997 |
[New preventive antimalaria drug. 3 tables, 2 months of protection. Interview by Petra Eiden].
Topics: Adolescent; Aminoquinolines; Antimalarials; Humans; Malaria; Randomized Controlled Trials as Topic | 2000 |
Drug use and design in the nineties.
Topics: Aminoquinolines; Amodiaquine; Antimalarials; Artemisinins; Calcium Channel Blockers; Chloroquine; Humans; Malaria; Mefloquine; Naphthoquinones; Phenanthrenes; Primaquine; Quinine; Sesquiterpenes; Sulfadoxine | 1991 |
Sporontocidal activity of the antimalarial WR-238605 against Plasmodium berghei ANKA in Anopheles stephensi.
Topics: Aminoquinolines; Animals; Anopheles; Antimalarials; Female; Insect Vectors; Malaria; Mice; Mice, Inbred ICR; Plasmodium berghei; Salivary Glands | 1990 |